Table 3.
Biomarker candidates and pathway analyses in studies included in systematic review of IBD
| Author (year) | Cohort | IBD type | Sample | Biomarker candidate | Pathway analysis |
|---|---|---|---|---|---|
| Manfredi et al. (2019) | Italy | CD | Serum | Fatty acid PUFA |
No |
| Iwatani et al. (2020) | Japan | CD | Plasma | PS | No |
| Horta et al. (2021) | Spain | Fatigue CD | Plasma | PC LPC PE PI PS SM Eicosanoid |
Yes |
| Guan et al. (2020) | China | CD/UC | Plasma | FA GP SL Prenol lipid Sterol lipid |
Yes |
| Daniluk et al. (2019) | Poland | CD | Serum | GP Cer |
Yes |
| Diab et al. (2019) | Norway | UC | Tissue | PC SM Cer |
No |
| Fan et al. (2015) | Australia | CD | Plasma | PC Ether PC Ether PE LPE PS Cer |
No |
| UC | |||||
| Bazarganipour et al. (2019) | Germany | UC | Plasma | Fatty acid LPC SM Cer TG Eicosanoid |
No |
| Tissue | |||||
| Jansson et al. (2009) | Sweden | CCD | Feces | FA | Yes |
| Murgia et al. (2018) | Italy | CD | Plasma | Fatty acid PC LPC PS TG |
No |
| Ehehalt et al. (2004) | Germany | CD | Tissue | PC LPC |
No |
| Bene et al. (2006) | Hungary | UC | Plasma | AcylCar | No |
| Pearl et al. (2014) | UK | UC | Tissue | Eicosanoid | No |
| Braun et al. (2009) | Germany | CD | Tissue | PC LPC SM |
No |
| Scoville et al. (2018) | US | CD | Serum | FA | Yes |
| Tefas et al. (2020) | Romania | CD | Serum | FA PC LPC SM DG |
Yes |
| Masoodi et al. (2013) | UK | UC | Tissue | Eicosanoid | No |
| Sewell et al. (2012) | UK | CD | Tissue, Cell | PI PC |
No |
| Lai et al. (2019) | US | Active CD | Serum | Fatty acid Acylcarnitine |
Yes |